A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer
Phase 1
- Conditions
- Esophageal Cancer
- Interventions
- Biological: OBP-301Radiation: Radiation
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Oncolys BioPharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT03213054
- Locations
- π―π΅
Research site, Kita, Okayama, Japan
A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Oncolys BioPharma Inc
- Target Recruit Count
- 17
- Registration Number
- NCT02414516
- Locations
- πΊπΈ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma
Phase 1
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Biological: OBP-301
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Oncolys BioPharma Inc
- Target Recruit Count
- 18
- Registration Number
- NCT02293850
- Locations
- π°π·
Pusan National University Hospital, Busan, Korea, Republic of
π¨π³National Taiwan University Hospital, Taipei, Taiwan
Β© Copyright 2025. All Rights Reserved by MedPath